Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 19, 2026Blood Cancer JournalOpen Access

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJuying WeiQCQingqing CaiLZLiling Zhang

Discussion

Loading...

Member takes

Overview

Phase 2 trial explores golidocitinib's effect on disease control in peripheral T cell lymphoma patients, suggesting potential benefits.

Key Points

  • This study aimed to evaluate the efficacy and safety of golidocitinib as maintenance therapy in patients with peripheral T cell lymphoma who responded to first-line treatment.
  • Multicenter phase 2 trial with two cohorts based on initial response (complete or partial).
  • Administered golidocitinib (150 mg daily) to patients in need of maintenance therapy.
  • Evaluated disease free survival and progression free survival rates at 24 months.
  • Monitored adverse events related to treatment.
  • Cohort 1 showed a 24-month disease free survival rate of 74.2%.
  • Cohort 2 had a median progression free survival of 17.4 months with a 24-month rate of 48.6%.
  • Half of the patients in Cohort 2 with initial partial response achieved complete response.
  • The most common serious adverse events were hematological, with manageable and reversible impacts.

Cite This Study

Wei et al. (2026) studied this question.

synapsesocial.com/papers/69bb9313496e729e62980dadhttps://doi.org/10.1038/s41408-026-01452-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib2025
  2. 2Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre2025
  3. 3Combination of golidocitinib (a JAK1 inhibitor) with anti–PD-1 antibody to improve tumor response and patient quality of life: Preliminary results from an ongoing JACKPOT 33 study.2026
  4. 4Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial2025 · 1 citations
  5. 5Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia2025